verve therapeutics - Search News

News

Eli Lilly Buys Verve Therapeutics

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a potential long-term growth.

UPI on MSN · 7h

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Seeking Alpha · 8h

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.

5hon MSN

These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

10hon MSN

Why Verve Therapeutics Stock Is Skyrocketing Today

Eli Lilly plans to acquire Verve for up to $1.3 billion. Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% ...

11hon MSN

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Benzinga.com10h

5 Analysts Assess Verve Therapeutics: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Verve Therapeutics VERV in the last three months. The table below provides a snapshot of their ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Eli Lilly Buys Verve Therapeutics

Related topics